Related Experiment Videos
[Recent progress in the chemotherapy program and its theoretical background--malignant lymphoma]
M Hirano1, M Okamoto, F Maruyama
1Department of Medicine, Fujita Health University School of Medicine.
Nihon Rinsho. Japanese Journal of Clinical Medicine
|June 1, 1992
Summary
Third generation chemotherapy improves survival for aggressive non-Hodgkin's lymphoma. Further advances may involve new drugs and stem cell transplantation for enhanced outcomes.
Area of Science:
- Oncology
- Hematology
- Pharmacology
Context:
- Aggressive non-Hodgkin's lymphoma (NHL) treatment has advanced with third-generation chemotherapy.
- These protocols are based on cancer chemotherapy principles and overcoming drug resistance.
Purpose:
- To evaluate the efficacy of third-generation chemotherapy protocols in aggressive NHL.
- To explore strategies for further improving disease-free survival (DFS) and complete remission (CR) rates.
Summary:
- Third-generation chemotherapy, exemplified by the CAMBO-VIP protocol, achieved a 90% CR and 76% DFS at 3 years in aggressive NHL patients.
- This approach utilizes multiple non-cross-resistant drugs at maximally elevated dose intensity.
- The study builds upon foundational cancer chemotherapy research by Skipper and Goldie/Coldman regarding drug resistance.
Impact:
- Demonstrates significant improvement in long-term DFS for aggressive NHL.
- Suggests future directions including novel drugs, resistance-targeting agents, and stem cell support (myelostimulatory cytokines, autologous/allogeneic stem cell transplantation) for enhanced dose intensity and patient outcomes.